Wide Ranks

APGE

Apogee Therapeutics, Inc.

44.70

Top Statistics
Market Cap 2 B Forward PE -11.56 Revenue Growth 0.00 %
Current Ratio 16.39 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 526 M Total Cash Per Share 8.99 Total Debt 12 M
Total Debt To Equity 1.65 Current Ratio 16.39 Book Value Per Share 12.55
All Measures
Short Ratio 1809.00 % Message Board Id finmb_1816591253 Shares Short Prior Month 6 M
Return On Equity -0.2565 City Waltham Uuid a31551ee-fb27-3439-a3c7-bbfae7df46cb
Previous Close 43.96 First Trade Date Epoch Utc 1 B Book Value 12.55
Total Debt 12 M Volume 539146 Price To Book 3.56
Fifty Two Week Low 17.17 Total Cash Per Share 8.99 Shares Short Previous Month Date 1 B
Target Median Price 89.00 Audit Risk 7 Max Age 86400
Recommendation Mean 1.00 Sand P52 Week Change 0.3133 Target Mean Price 88.71
Net Income To Common -146663008 Short Percent Of Float 0.1713 Implied Shares Outstanding 58 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 496210
Average Volume10days 496210 Total Cash 526 M Next Fiscal Year End 1 B
Held Percent Insiders 0.1171 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 10 Regular Market Previous Close 43.96
Target Low Price 75.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 53.82
Open 45.08 Free Cashflow -86914000 State MA
Dividend Yield 0.00 % Return On Assets -0.1852 Time Zone Short Name EST
Board Risk 6 Trailing Eps -2.43 Day Low 43.95
Address1 221 Crescent Street Shares Outstanding 43 M Compensation Risk 9
Price Hint 2 Target High Price 100.00 Website https://www.apogeetherapeutics.com
52 Week Change 1.29 Average Volume 427514 Forward Eps -3.80
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1627.70 %
Is_sp_500 False Regular Market Day High 45.38 Profit Margins 0.00 %
Debt To Equity 1.65 Fifty Two Week High 72.29 Day High 45.38
Shares Short 6 M Regular Market Open 45.08 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.1164
Operating Cashflow -133214000 Currency USD Time Zone Full Name America/New_York
Market Cap 2 B Is_nasdaq_100 False Zip 02453
Quote Type EQUITY Industry Biotechnology Long Name Apogee Therapeutics, Inc.
Overall Risk 9 Regular Market Day Low 43.95 Held Percent Institutions 1.27
Current Price 44.70 Address2 Building 17 Suite 102b Financial Currency USD
Current Ratio 16.39 Industry Disp Biotechnology Number Of Analyst Opinions 7
Country United States Float Shares 29 M Two Hundred Day Average 50.08
Governance Epoch Date 1 B Enterprise Value 2 B Forward PE -11.56
Regular Market Volume 539146 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.

The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.

Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.